Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 24, 2013 - Issue 3
Submit an article Journal homepage
887
Views
36
CrossRef citations to date
0
Altmetric
Non-melanoma skin cancer

Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how

Vincenzo BettoliDepartment of Clinical and Experimental Medicine, Section of Dermatology, University of Ferrara, Arcispedale S. Anna, Ferrara, ItalyCorrespondence[email protected]
,
Stefania ZauliDepartment of Clinical and Experimental Medicine, Section of Dermatology, University of Ferrara, Arcispedale S. Anna, Ferrara, Italy
&
Anna VirgiliDepartment of Clinical and Experimental Medicine, Section of Dermatology, University of Ferrara, Arcispedale S. Anna, Ferrara, Italy
Pages 235-237 | Received 30 May 2012, Accepted 23 Jul 2012, Published online: 03 Feb 2013

References

  • Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol. 2007;156:1–7.
  • Dragnev KH, Rigas JR, Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist. 2000;5:361–368.
  • Prado R, Francis SO, Mason MN, Wing G, Gamble RG, Dellavalle R. Nonmelanoma skin cancer chemoprevention. Dermatol Surg. 2011;37:1566–1578.
  • Amann PM, Eichmüller SB, Schmidt J, Bazhin AV. Regulation of gene expression by retinoids. Curr Med Chem. 2011;18:1405–1412.
  • Chen JY, Penco S, Ostrowski J, Balaguer P, Pons M, Starrett JE, et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 1995;14:1187–1197.
  • Cheepala SB, Yin W, Syed Z, Gill JN, McMillian A, Kleiner HE, et al. Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer. 2009;8:27.
  • Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA. 1997;94:12070–12074.
  • Mrass P, Rendl M, Mildner M, Gruber F, Lengauer B, Ballaun C, et al. Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Res. 2004;64:6542–6548.
  • Moon TE, Levine N, Cartmel B, Bangert JL. Retinoids in prevention of skin cancer. Cancer Lett. 1997;114:203–205.
  • Tangrea JA, Edwards BK, Taylor PR, Hartman AM, Peck GL, Salasche SJ, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst. 1992;84:328–332.
  • Kraemer KH, DiGiovanna JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol. 1992;19:715–718.
  • Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med. 1988;318:1633–1637.
  • De Graaf YG, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg. 2004;30:656–661.
  • Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol. 2003;49:644–650.
  • Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg. 2006;32:562–568.
  • Marquez C, Bair SM, Smithberger E, Cherpelis BS, Glass LF. Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol. 2010;9:753–758.
  • Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs. 1997;53:358–388.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.